NCT04821674

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: Daiichi Sankyo Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 74 Years
• Healthy volunteers: Accepted

Summary

This study will assess the safety, tolerability and immunogenicity of DS-5670a (COVID-19 Vaccine) and determine the recommended dose in Japanese healthy adults and elderly participants.

Conditions

• Covid19

Interventions

Type	Name	Description
BIOLOGICAL	DS-5670a	DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
BIOLOGICAL	Placebo	Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total

Timeline

• Start date: 2021-03-15
• Primary completion: 2021-08-13
• Completion: 2022-07-14
• First posted: 2021-03-29
• Last updated: 2022-08-30

Locations

1 site across 1 country: Japan